NextGen Scientific Announces $10M Regulation D Capital Raise

Funds to support oncology and dermatology drug development, as well as nutraceutical business

Mar. 30, 2026 at 4:23pm

Got story updates? Submit your updates here. ›

NextGen Scientific, a life sciences company focused on advancing oncology and dermatology drug development, has announced a $10 million Regulation D, Rule 506(c) private placement offering to accredited investors. The proceeds will be used to acquire ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences, to support clinical and preclinical programs for oncology and dermatology drug candidates, as well as the company's nutraceutical business.

Why it matters

This capital raise will allow NextGen Scientific to further develop its pipeline of oncology and dermatology drug candidates, while also expanding its nutraceutical business. The investment in Ionics Life Sciences and its subsidiaries provides exposure to both clinical-stage drug development and a revenue-generating, science-driven nutritional supplements business, diversifying NextGen's healthcare platform.

The details

The $10 million Regulation D, Rule 506(c) private placement offering will be used to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries. Genzada Pharmaceuticals USA, an early-stage biotech company focused on oncology drug development, has two clinical-stage drug candidates, GZ17-6.02 and GZ21T, that will receive funding for clinical and preclinical development. Hyatt Life Sciences, a revenue-generating nutraceutical and botanical sciences enterprise, will also benefit from the capital raise to support its science-based dietary supplement business.

  • NextGen Scientific issued the updated announcement on March 27, 2026.
  • GZ21T is expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial in actinic keratosis patients in Sweden and the Netherlands.

The players

NextGen Scientific LLC

A life sciences company focused on advancing oncology and dermatology drug development while participating in the commercialization of science-backed wellness products.

Ionics Life Sciences Limited

A company that NextGen Scientific is acquiring up to 3.1% ownership in, which includes subsidiaries Genzada Pharmaceuticals USA and Hyatt Life Sciences.

Genzada Pharmaceuticals USA

An early-stage biotechnology company focused on oncology drug development, with two clinical-stage drug candidates and additional assets in development.

Hyatt Life Sciences

A revenue-generating nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements.

Cameron West, MD, FAAD

The Chief Operating Officer of NextGen Scientific.

Got photos? Submit your photos here. ›

What they’re saying

“During our Phase I dose escalation study for GZ17-6.02, we observed promising biological effect against a broad array of cancer types and we are excited to further explore how this translates into meaningful clinical impact.”

— Cameron West, MD, FAAD, Chief Operating Officer

“In addition, based on the significant body of preclinical data and the promising preliminary safety profile of GZ21T, I am optimistic that it has the potential to deliver game changing results in a multitude of dermatologic conditions.”

— Cameron West, MD, FAAD, Chief Operating Officer

What’s next

NextGen Scientific plans to use the proceeds from the $10 million Regulation D offering to support the clinical and preclinical development of its oncology and dermatology drug candidates, as well as targeted marketing initiatives for its nutraceutical business.

The takeaway

This capital raise allows NextGen Scientific to advance its diversified healthcare platform, which includes both clinical-stage drug development and a revenue-generating nutraceutical business. The investment in Ionics Life Sciences and its subsidiaries provides exposure to promising oncology and dermatology drug candidates, as well as a growing science-backed supplements enterprise.